Ono Pharmaceutical Co. Ltd. has entered into a worldwide drug discovery collaboration agreement with Macomics Ltd. to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer.
Oxford Drug Design Ltd. has been engaged by Phoremost Ltd. to accelerate a targeted protein degradation discovery program that seeks to identify new E3 ligase-based therapeutic strategies to treat cancer.
Shuttle Pharmaceuticals Holdings Inc. has entered a research agreement with Georgetown University focused on the evaluation of the company's lead histone deacetylase 6 (HDAC6) inhibitor candidate, SP-2-225, evaluating the antitumor effect of the combination of SP-2-225 and radiation therapy in a syngeneic breast cancer model.
Charm Therapeutics Ltd. has entered into a strategic discovery collaboration with Bristol Myers Squibb Co. for the identification and optimization of compounds against Bristol Myers Squibb's selected targets.
Modex Therapeutics Inc., an Opko Health Inc. company, has entered into an exclusive worldwide license and collaboration agreement with Merck & Co. Inc., for the development of MDX-2201, Modex's preclinical nanoparticle vaccine candidate targeting Epstein-Barr virus (EBV).
Sisaf Ltd. has entered into a collaboration with the University of Leipzig to develop Bio-Courier targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer.
RSS
